滑膜肉腫治療の世界市場：2024年～2031年

概要

世界の滑膜肉腫治療市場は、2023年に8億3,247万米ドルに達し、2031年には16億4,661万米ドルに達すると予測され、予測期間2024年にはCAGR 8.9％で成長する見込みです。

滑膜肉腫はまれなタイプの軟部肉腫で、腕、脚、足の深部の組織に最も頻繁に発生します。滑膜細胞肉腫とも呼ばれるこれらの悪性（がん性）腫瘍は、滑膜関節（肘や臀部などの一般的な関節）の細胞に類似していることからその名がつきました。

滑膜肉腫は軟部組織のがんの5～10％を占めます。滑膜肉腫の治療には通常、手術、放射線療法、化学療法が併用されます。具体的な治療方針は、腫瘍の大きさ、部位、病期、患者の全身の健康状態や個人の嗜好によって異なります。

市場力学：

促進要因

滑膜肉腫の研究開発およびFDA承認の増加

世界の滑膜肉腫治療市場の需要は、複数の要因によって牽引されています。主な要因の1つは、最近の様々な研究開発により市場が大きく成長していることです。滑膜肉腫は30歳未満の若い患者に最もよく発生します。全体では軟部肉腫全体の約8％を占めるが、思春期や若年成人では15～20％を占めます。

例えば、2022年12月、Adaptimmune Therapeutics社は、滑膜肉腫の治療を目的としたMAGE-A4を標的とする第一世代の人工TCR T細胞療法であるAfami-celの生物製剤承認申請（BLA）の開始を発表しました。アファミセルの生物製剤承認申請は、アダプトイミューンの進行滑膜肉腫患者を対象としたSPEARHEAD-1臨床試験から得られた良好な臨床データによって裏付けられています。したがって、上記の要因により、市場は予測期間中に拡大すると予想されます。

さらに、滑膜肉腫治療に対するFDA承認の増加は、この市場の成長を促進すると思われます。例えば、2022年12月に食品医薬品局（FDA）は、切除不能または転移性の肺胞軟組織肉腫（ASPS）の成人および2歳以上の小児患者を対象にアテゾリズマブ（テセントリク、ジェネンテック社）を承認しました。アテゾリズマブ15mg/kgを21日毎に1回投与した場合の有効性が小児患者で検証されました。

また、C4 Therapeutics, Inc.は2022年3月、米国食品医薬品局（FDA）が軟部肉腫の治療薬としてCFT8634に希少疾病用医薬品（ODD）の指定を与えたと発表しました。

抑制要因

高額な治療費、免疫療法に伴う副作用、認知度・診断不足、限られた治療選択肢、厳しい規制要件・償還問題などの要因が市場抑制要因になると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 滑膜肉腫に対する研究開発の高まりとFDA承認の増加
    • 診断技術の進歩
  • 抑制要因
    • 治療費の高騰
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• アンメットニーズ
• 規制分析

第6章 治療法別

• 血管新生阻害薬
• 放射線療法
• 化学療法
• 標的療法
• 免疫療法
• その他

第7章 エンドユーザー別

• 病院
• 腫瘍センター
• 外来手術センター
• その他

第8章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
    • アルゼンチン
    • その他南米
• アジア太平洋
  • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋
• 中東・アフリカ

第9章 競合情勢

• 競合シナリオ
• 製品ベンチマーク
• 企業シェア分析
• 主な発展と戦略

第10章 企業プロファイル

• Pfizer Inc.
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Dr Reddy's Laboratories
• Hetero Healthcare
• Teva Pharmaceuticals
• Sterling Biotech Ltd.
• Baxter International
• Janssen Pharmaceuticals
• Concord Biotech Ltd.
• Novartis AG
• Taiho Pharmaceuticals

第11章 付録

Overview

The global synovial sarcoma treatment market reached US$ 832.47 million in 2023 and is expected to reach US$ 1646.61 million by 2031 growing with a CAGR of 8.9% during the forecast period 2024-2031.

Synovial sarcoma is a rare type of soft tissue sarcoma that develops most frequently in tissues deep within the arms, legs, and feet. Also called synovial cell sarcoma, these malignant (cancerous) tumors got their name from similarities to cells in synovial joints-common joints such as the elbows and hips.

Synovial sarcoma accounts for 5% to 10% of soft-tissue cancers. The treatment for synovial sarcoma typically involves a combination of surgery, radiation therapy, and chemotherapy. The specific treatment plan will depend on the size, location, and stage of the tumor, as well as the patient's overall health and personal preferences.

Market Dynamics: Drivers

Rising Research and Developments & Increasing FDA Approvals for Synovial Sarcoma

The demand for the global synovial sarcoma treatment market is driven by multiple factors. One of the key factors is the market has grown significantly due to various recent research and developments. Synovial sarcoma occurs most commonly in the younger patients under 30 years of age. While overall comprising about 8% of all soft tissue sarcomas, it accounts for 15-20% of the cases in adolescents and young adults.

For instance, in December 2022, Adaptimmune Therapeutics announced the initiation of biologics license application (BLA) submission for Afami-cel which is their first-generation engineered TCR T-cell therapy targeting MAGE-A4 for the treatment of synovial sarcoma. The biologics license submission for afami-cel is supported by positive clinical data from Adapt Immune's SPEARHEAD-1 clinical trial in patients with advanced synovial sarcoma. Thus, owing to the above factors the market is expected to boost over the forecast period.

Moreover, increasing FDA approvals for the synovial sarcoma treatment would propel this market growth. For instance, in December 2022, the Food and Drug Administration (FDA) approved atezolizumab (Tecentriq, Genentech, Inc.) for adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft tissue sarcoma (ASPS). The efficacy of atezolizumab 15 mg/kg given once every 21 days was tested in pediatric patients.

Also, in March 2022, C4 Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to CFT8634 for the treatment of soft tissue sarcoma.

Restraints

Factors such as the high cost of the treatment, side effects associated with the immunotherapy, lack of awareness & diagnosis, limited treatment options, and stringent regulatory requirements & reimbursement issues, are expected to hamper the market.

Segment Analysis

The global synovial sarcoma treatment market is segmented based on treatment, end users, and region.

The immunotherapy segment accounted for approximately 45.3% of the global synovial sarcoma treatment market share

The immunotherapy segment is expected to hold the largest market share over the forecast period. Immunotherapy includes drugs that activate the immune system that modify the immune system cells to target tumor cells and monoclonal antibodies, checkpoint inhibitors, and vaccines are the common types of immunotherapies.

The rising number of clinical trials for immunotherapy and the increasing approvals of immunotherapy drugs have contributed to the growing demand for synovial sarcoma treatment. For instance, in February 2024, Immunotherapy before surgery leads to promising long-term survival in sarcoma patients. MD Anderson-led Phase II trial suggests neoadjuvant immunotherapy is safe and may be an effective option for patients with soft-tissue sarcomas.

Similarly, in March 2024, an immunotherapy clinical trial showed promise for treating rare sarcomas. Now, a phase 2 clinical trial testing an experimental cell therapy called afamitresgene autoleucel (afami-cel) found that it significantly shrank sarcoma tumors in more than one-third of patients.

Also, in October 2023, the Clinical Cancer Research publication stated that the immunotherapy with TBI-1301 to target NY-ESO-1-positive tumor cells demonstrated promising results for the treatment of advanced or recurrent synovial sarcoma.

Geographical Analysis

North America accounted for approximately 42.3% of the global synovial sarcoma market share

North America region is expected to hold the largest market share over the forecast period owing to factors such as the rising prevalence of soft tissue sarcoma, increasing research and developments, and technological advancements in synovial sarcoma treatment.

According to the American Cancer Society, the estimation for soft tissue sarcomas in the United States for 2023 is around 13,400 new soft tissue sarcomas that will be diagnosed (7,400 in males and 6,000 in females) and about 5,140 people are expected to die of soft tissue sarcomas. The increasing number of synovial sarcoma diagnoses creates a pressing demand for effective treatments in this region.

In addition, a well-advanced healthcare system, rising clinical trials, and research studies in the treatment of synovial sarcoma would propel this market growth. For instance, in May 2023, Immatics provided an interim update on cohort A of its Phase Ib dose-expansion trial evaluating its leading T-cell receptor-based therapy (TCR-T) candidate IMA203. The best responders to IMA203 in the small cohort were patients with cutaneous and uveal melanoma, synovial sarcoma, and platinum-resistant ovarian cancer.

Also, in June 2023, Replay Holdings LLC and The University of Texas MD Anderson Cancer Center announced that the FDA has cleared the IND application for NY-ESO-1 TCR/IL-15 NK, an engineered T-cell receptor natural killer (TCR-NK) cell therapy for advanced synovial sarcoma and myxoid/round cell liposarcoma.

Market Segmentation

By Treatment

• Anti-angiogenesis Drugs
• Radiation Therapy
• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Others

By End Users

• Hospitals
• Oncology centers
• Ambulatory Surgical centers
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the synovial sarcoma market include Pfizer Inc., Dr. Reddy's Laboratories, Hetero Healthcare, Teva Pharmaceuticals, Sterling Biotech Ltd., Baxter International, Janssen Pharmaceuticals, Concord Biotech Ltd., Novartis AG, Taiho Pharmaceuticals among others.

Key Developments

• In February 2024, the FDA accepted for priority review the biologics license application (BLA) seeking the approval of afamitresgene autoleucel (afami-cel), an investigational engineered T-cell therapy, for the treatment of patients with advanced synovial sarcoma.
• In December 2023, the grand opening of HKSH's proton therapy center marks a significant advancement in precision cancer treatment in Hong Kong. All six pediatric cancer cases were referred by the Hong Kong Children's Hospital. These pediatric cases involve neuroblastoma, synovial sarcoma, maxillary sinus sarcoma, maxillary sinus carcinoma, and craniopharyngioma.
• In October 2023, Takara Bio Inc., announced that the results from the clinical trial of NY-ESO-1*siTCRTM gene therapy for patients with advanced or recurrent synovial sarcoma were published in Clinical Cancer Research Online, a journal of the American Association for Cancer Research (AACR).
• In February 2023, Medsafe approved the use of YONDELIS (trabectedin) for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.

Why Purchase the Report?

• To visualize the global synovial sarcoma treatment market segmentation based on the treatment, end users, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global synovial sarcoma treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global synovial sarcoma treatment market report would provide approximately 54 tables, 47 figures, and 182 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Treatment
• 3.2. Snippet by End Users
• 3.3. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising Research and Developments & Increasing FDA Approvals for Synovial Sarcoma
    • 4.1.1.2. Advancements in the Diagnostic Technologies
  • 4.1.2. Restraints
    • 4.1.2.1. High Cost of the Treatment
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Unmet Needs
• 5.4. Regulatory Analysis

6. By Treatment

• 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
• 6.1.2. Market Attractiveness Index, By Treatment
• 6.2. Anti-angiogenesis Drugs
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Radiation Therapy
• 6.4. Chemotherapy
• 6.5. Targeted Therapy
• 6.6. Immunotherapy
• 6.7. Others

7. By End Users

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
  • 7.1.2. Market Attractiveness Index, By End Users
• 7.2. Hospitals*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Oncology Centers
• 7.4. Ambulatory Surgical Centers
• 7.5. Others

8. By Region

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 8.1.2. Market Attractiveness Index, By Region
• 8.2. North America
  • 8.2.1. Introduction
  • 8.2.2. Key Region-Specific Dynamics
  • 8.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 8.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
  • 8.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 8.2.5.1. U.S.
    • 8.2.5.2. Canada
    • 8.2.5.3. Mexico
• 8.3. Europe
  • 8.3.1. Introduction
  • 8.3.2. Key Region-Specific Dynamics
  • 8.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 8.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
  • 8.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 8.3.5.1. Germany
    • 8.3.5.2. U.K.
    • 8.3.5.3. France
    • 8.3.5.4. Italy
    • 8.3.5.5. Spain
    • 8.3.5.6. Rest of Europe
• 8.4. South America
  • 8.4.1. Introduction
  • 8.4.2. Key Region-Specific Dynamics
  • 8.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 8.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
  • 8.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  • 8.4.6. Brazil
    • 8.4.6.1. Argentina
    • 8.4.6.2. Rest of South America
• 8.5. Asia Pacific
  • 8.5.1. Introduction
  • 8.5.2. Key Region-Specific Dynamics
  • 8.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 8.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
  • 8.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  • 8.5.6. China
    • 8.5.6.1. India
    • 8.5.6.2. Japan
    • 8.5.6.3. South Korea
    • 8.5.6.4. Rest of Asia Pacific
• 8.6. Middle East and Africa
  • 8.6.1. Introduction
  • 8.6.2. Key Region-Specific Dynamics
  • 8.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 8.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users

9. Competitive Landscape

• 9.1. Competitive Scenario
• 9.2. Product Benchmarking
• 9.3. Company Share Analysis
• 9.4. Key Developments and Strategies

10. Company Profiles

• 10.1. Pfizer Inc.*
  • 10.1.1. Company Overview
  • 10.1.2. Product Portfolio and Description
  • 10.1.3. Financial Overview
  • 10.1.4. Key Developments
• 10.2. Dr Reddy's Laboratories
• 10.3. Hetero Healthcare
• 10.4. Teva Pharmaceuticals
• 10.5. Sterling Biotech Ltd.
• 10.6. Baxter International
• 10.7. Janssen Pharmaceuticals
• 10.8. Concord Biotech Ltd.
• 10.9. Novartis AG
• 10.10. Taiho Pharmaceuticals

LIST NOT EXHAUSTIVE

11. Appendix

• 11.1. About Us and Services
• 11.2. Contact Us